EGFR and lung carcinoma: In 2019, Jin group designed a new class of EGFR PTOACs based on Gefitinib and different E3 ligands.51 The degrader 22 (MS39, Fig. 7) and degrader 23 (MS154, Fig. 7) which were based on VHL and CRBN potently induced the selective degradation of EGFR mutants but not EGFRWT and inhibited lung cancer cells proliferation.